Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
1.140
+0.010 (0.88%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Boundless Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-58.2-65.36-49.43-45.9-25.21
Depreciation & Amortization
1.251.090.960.940.68
Loss (Gain) From Sale of Investments
-2.59-5.06-3.30.50.54
Stock-Based Compensation
6.137.523.342.291.16
Other Operating Activities
3.292.652.391.70.42
Change in Accounts Payable
1.630.781.661.911.22
Change in Other Net Operating Assets
1.83-2.45-2.46-1.05-2.06
Operating Cash Flow
-46.66-60.84-46.86-39.6-23.25
Capital Expenditures
-0.55-2.54-0.63-1.07-2.03
Investment in Securities
38.35-23.57-37.6317.2-57.25
Investing Cash Flow
37.8-26.1-38.2616.13-59.29
Issuance of Common Stock
0.1493.170.180.130.21
Other Financing Activities
--3.35-1.96--
Financing Cash Flow
0.1489.8297.90.13105.53
Net Cash Flow
-8.722.8812.78-23.3422.99
Free Cash Flow
-47.21-63.38-47.49-40.66-25.28
Free Cash Flow Per Share
-2.11-3.73-39.05-37.04-29.38
Levered Free Cash Flow
-37.53-37.58-30.95-24.76-
Unlevered Free Cash Flow
-37.53-37.58-30.95-24.76-
Change in Working Capital
3.46-1.68-0.80.87-0.84
Source: S&P Capital IQ. Standard template. Financial Sources.